This is a randomized, open-label, dose-finding, multi-centre, phase b study to evaluate the efficacy and safety of JMT103 in patients with bone metastases from solid tumors.
The objective of this trial is to evaluate the efficacy and safety of JMT103 in patients with bone metastases from solid tumors.
Eligible patients will be randomly assigned to receive JMT103 120mg subcutaneously (SC) every 4 weeks (Q4W), 120mg subcutaneously (SC) every 8 weeks (Q8W) and 180mg subcutaneously (SC) every 8 weeks (Q8W) in a 1:1:1 ratio. Patients will receive the treatment until the completion of 48 weeks of treatment, intolerable toxicity, loss to follow-up, withdrawal (patient's decision or investigator's decision), whichever comes first.
| Condition | Bone Metastases From Solid Tumors |
|---|---|
| Treatment | Drug: JMT103- 120 mg SC Q4W, Drug: JMT103- 120 mg SC Q8W, Drug: JMT103- 180 mg SC Q8W, Dietary Supplement: Calcium Dietary Supplement: Vitamin D |
| Clinical Study Identifier | NCT04630522 |
| Sponsor | Shanghai JMT-Bio Inc. |
| Last Modified on | 3 July 2022 |
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteer
Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!
No annotations made yet
Congrats! You have your own personal workspace now.